A Prospective Safety Sub-Registsry to Assess Anaphylaxis and Severe Allegric Reactions and Severe Cutaneious and Systemic Immune-mediated Reactions with Alglucosidase Alfa Treatment

Administered By

Awarded By

Contributors

Start/End

  • October 10, 2016 - September 30, 2021